Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for a new chemical raw material drug, indicating a significant development in its product pipeline [1] Group 1: Company Developments - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" from the National Medical Products Administration [1] - The approved chemical raw material is named Clobetasol, which is a phosphodiesterase 4 (PDE-4) inhibitor [1] - Clobetasol ointment is indicated for local external treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1]